Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

September 8, 2017September 8, 2017

Tumor DNA in Blood Used to Detect Many Early-stage Ovarian and Other Cancers in Study

News

Using a modern DNA sequencing technique, Johns Hopkins researchers have come one step closer to diagnosing early-stage cancer patients with a simple blood draw. The method reads free circulating DNA in ... Read more

September 6, 2017

Phase 1 Clinical Trial Is Assessing Cantrixil in Ovarian Cancer Patients Who Are Resistant to Chemo

News

Three Australian and two American cancer centers are spearheading the first clinical trial of Cantrixil, Novogen’s therapy to restore ovarian cancer patients’ sensitivity to chemotherapy. Associate Professor Jim Coward, an oncologist at ... Read more

August 28, 2017

Cancer Research UK Tests Therapy for Advanced Ovarian, Other Cancers in Phase 1 Trial

News

An investigational therapy called LY3143921 hydrate will be tested for the first time in a large Phase 1 clinical trial for patients with advanced cancers, including ovarian cancer. The trial ... Read more

August 16, 2017August 16, 2017

Trial of Vaccine to Prevent Ovarian Cancer Recurrence Expands to Advanced-stage Patients

News

TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer. While the study initially aimed to enroll 80 patients, it is ... Read more

August 14, 2017

BMS and Clovis Collaborate to Test Opdivo, Rubraca Combo Therapy in Ovarian, Other Cancer Types

News

A new clinical collaboration has been established between Bristol-Myers Squibb (BMS) and Clovis Oncology to evaluate the performance of Opdivo (nivolumab) in combination with Rubraca (rucaparib) in a Phase 3 trial for advanced ovarian cancer. ... Read more

May 5, 2017May 5, 2017

Celsion’s GEN-1 Immunotherapy Could Help Women with Advanced Ovarian Cancer, Trial Shows

News

Celsion has released the latest update from the its OVATION Phase 1b clinical trial (NCT02480374), showing that combining GEN-1 with standard of care for newly diagnosed advanced ovarian cancer patients induces superior progression-free survival (PFS) rates ... Read more

April 24, 2017April 24, 2017

World’s First Personalized Ovarian Cancer Vaccine Trial Recruits Patients at UConn Health

News

The University of Connecticut Health Center (UConn Health) is recruiting ovarian cancer patients for the world’s first clinical trial testing a personalized genomics-driven vaccine (NCT02933073). The vaccine, called OncoImmunome, targets women with ... Read more

May 26, 2016May 26, 2016

COPD’s Unmet Milestones Discussed at 2016 REG Summit

News

During this year’s Respiratory Effectiveness Group (REG) Summit (2016 REG Summit), researchers from around the globe highlighted the urgent need for more research into current therapies for chronic obstructive pulmonary ... Read more